Oncocyte appoints Joshua Riggs as permanent CEO, President, and Board member

Insight Molecular Diagnostics Inc.

Joshua Riggs appointed CEO effective Feb 24, 2023; also named President and joined Board on Feb 28.
Riggs served as interim CEO since Dec 2022, leading restructuring and cost reduction initiatives.
Board unanimously supports Riggs' appointment; Chair Andy Arno cites rapid spend reduction and strategic refocus.
Riggs previously held roles as General Manager, Transplant and Senior Director of Business Development at Oncocyte.
Company continues focus on precision diagnostics: DetermaIO, VitaGraft, and pipeline test DetermaCNI.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua Riggs

Chief Executive Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-02-24
Filed: March 2, 2023, 6:59 PM ET

Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.

Appointed

Joshua Riggs

Director

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-02-28
Filed: March 2, 2023, 6:59 PM ET

Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.

Appointed

Joshua Riggs

President

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-02-28
Filed: March 2, 2023, 6:59 PM ET

Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Riggs was appointed as Director at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Director

Exact text from the filing

Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Riggs was appointed as President at Insight Molecular Diagnostics Inc..

Action: appointed
Role: President

Exact text from the filing

Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.